Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on November 1, 2017. The report details a material definitive agreement entered into on the same date regarding a private placement financing.
Key Financial Metrics
- Financing Proceeds: $2,000,000 in aggregate gross proceeds.
- Instrument: Sale of 2,000 shares of Series F Convertible Preferred Stock.
- Purchase Price: $1,000 per Preferred Share.
- Conversion Price: $0.15 per share of common stock.
- Use of Proceeds: General corporate purposes, including paying down obligations and working capital.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the issuance of Series F Convertible Preferred Stock to accredited investors. This transaction increases the company's capital base and introduces new equity holders with specific anti-dilution, redemption, and liquidation rights. The filing does not provide comparative financial data to quantify changes versus prior periods.
Guidance, Outlook, and Risks
- Management Commentary: The company intends to use proceeds to reduce obligations and fund working capital.
- Registration Rights: The company agreed to file a registration statement for the resale of underlying common stock within 30 days. If the statement is not effective within specified timeframes, the company must pay a penalty of 2.0% of the aggregate purchase price per month.
- Ownership Limitations: Conversion is limited to prevent any holder from acquiring more than 4.99% of outstanding common stock (increasable to 9.99% in certain circumstances).
- Risks: Potential cash outflows if registration rights deadlines are missed; dilution upon conversion of preferred shares.
Investor Verification Checklist
- Verify the company name discrepancy (Filing lists Nemus Bioscience, Inc.; metadata lists Skye Bioscience, Inc.).
- Confirm the status of the registration statement for the underlying common stock to assess potential 2% monthly penalty fees.
- Review the Certificate of Designation (Exhibit 3.1) for specific details on anti-dilution and liquidation preferences.
- Assess the company's current debt obligations to understand the impact of the "pay down obligations" use of proceeds.
- Check subsequent filings for the effective date of the resale registration statement.